LLY Research Note — Share Lead Meets Valuation
Lilly’s Q2 revenue rose 48% as category share widened, leaving paid access and recurring margins as the next valuation tests.
LLY
LLY Deep Coverage Review — Analysis as of August 13, 2026
Lilly’s market-share lead and oral pipeline support growth, but recurring margins must justify a valuation near 41 times trailing earnings.
LLY Research Note — Proof After the Gap
Lilly’s post-earnings evidence preserved the franchise case, but recurring margins and oral-program progress still have to support the valuation.
LLY Deep Coverage Review — Analysis as of August 6, 2026
Lilly’s franchise remains powerful, but the post-earnings tape and recurring margin bridge leave its premium valuation under a harder test.
LLY Research Note — Franchise Strength Meets Valuation Risk
Lilly’s incretin franchise remains powerful, while valuation, policy and access risks make the August 5 evidence window unusually important.
LLY Deep Coverage Review — Analysis as of July 27, 2026
Lilly’s incretin growth and oral launch support the franchise, while valuation, policy and access risks raise the evidence bar for August 5.